Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data from Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer Oct 2, 2018
Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Aug 30, 2018
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer Aug 21, 2018
